Newsmakers

Wellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ Pharmacies

TAMPA, FL  / September 30, 2025 / Wellgistics Health, Inc. (“Wellgistics Health” or the “Company”) (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, […]

Newsmakers

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these […]

Newsmakers

Wellgistics Health (NASDAQ: WGRX) Launches Capital Access Program for 6,500+ Pharmacies and Supply Chain Partners, Unlocking up to $1M in Working Capital

In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience. TAMPA, FL / September […]

Newsmakers

Advent Technologies (NASDAQ: ADN) Delivers State-of-the-Art Portable Fuel Cell Systems under Contract with the U.S. Department of Defense

LIVERMORE, Calif., Sept. 22, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in fuel cells and hydrogen technologies, has delivered its next generation, state-of-the-art Honey Badger 50™ (“HB50”) portable power units to […]

Newsmakers

Advent Technologies (NASDAQ: ADN) Announces Major Milestone in its Strategic Collaboration with Airbus

LIVERMORE, Calif., Sept. 09, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN) an innovation-driven leader in the fuel cell and hydrogen technology sector, is proud to announce a major technological breakthrough in its strategic collaboration […]

Newsmakers

Hoth Therapeutics (NASDAQ: HOTH) Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

NEW YORK, Sept. 10, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of […]